The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib in Ulcerative Colitis Pharmaceutical Investing
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab in Crohn's Disease Pharmaceutical Investing
NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022 Market News
Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy Pharmaceutical Investing
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV Pharmaceutical Investing
Awakn Life Sciences Files Patent Cooperation Treaty Application for the Treatment of Behavioral Addictions Company News
Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference Pharmaceutical Investing
LAWSUITS FILED AGAINST ABBV, AXSM and OKTA - Jakubowitz Law Pursues Shareholders Claims Pharmaceutical Investing
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCID, IBM and AUPH Pharmaceutical Investing
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ABBV, NTRA and CDNA Pharmaceutical Investing
ABBV ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc. Pharmaceutical Investing
